CoChat
Sign Up
Cited by 870Atrial Fibrillation Management and OutcomesAcute Ischemic Stroke ManagementVenous Thromboembolism Diagnosis and Management

Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range

Connolly, Stuart J., Pogue, Janice, Eikelboom, John, Flaker, Gregory, Commerford, Patrick, Franzosi, Maria Grazia, Healey, Jeffrey S., Yusuf, Salim·2008·Circulation
DOI 10.1161/circulationaha.107.750000
Open this paper in CoChat — free account

Abstract

BACKGROUND: Oral anticoagulation (OAC) therapy is effective in atrial fibrillation but requires vigilance to maintain the international normalized ratio in the therapeutic range. This report examines how differences in time in therapeutic range (TTR) between centers and between countries affect the outcomes of OAC therapy. METHODS AND RESULTS: In a posthoc analysis, the TTRs of patients on OAC in a randomized trial of OAC versus clopidogrel plus aspirin (Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events [ACTIVE W]) were used to calculate the mean TTR for each of 526 centers and 15 countries. Proportional-hazards analysis, with and without adjustment for baseline variables, was performed, with patients stratified by TTR quartile and country. A wide variation in TTRs was found between centers, with mean TTRs for centers in the 4 quartiles of 44%, 60%, 69%, and 78%. For patients at centers below the median TTR (65%), no treatment benefit was demonstrated as measured by relative risk for vascular events of clopidogrel plus aspirin versus OAC (relative risk, 0.93; 95% confidence interval, 0.70 to 1.24; P=0.61). However, for patients at centers with a TTR above the study median, OAC had a marked benefit, reducing vascular events by >2-fold (relative risk, 2.14; 95% confidence interval, 1.61 to 2.85; P<0.0001). Mean TTR also varied between countries from 46% to 78%; relative risk (clopidogrel plus aspirin versus OAC) varied from 0.6 to 3.6 (a 5-fold difference). A population-average model predicted that a TTR of 58% would be needed to be confident that patients would benefit from being on OAC. CONCLUSIONS: A wide variation exists in international normalized ratio control, as measured by TTR, between clinical centers and between countries, which has a major impact on the treatment benefit of OAC therapy. For centers and countries, a target threshold TTR exists (estimated between 58% and 65%) below which there appears to be little benefit of OAC over antiplatelet therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.107.750000

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Connolly, S. J., Pogue, J., Eikelboom, J., Flaker, G., Commerford, P., Franzosi, M. G., Healey, J. S., & Yusuf, S.
Affiliations
  • University of Cape Town (ZA)
  • From the Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada (S.J.C., J.P., J.E., J.S.H., S.Y.); University of Missouri, Columbia (G.F.); Cardiac Clinic, Department of Medicine, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa (P.C.); and Department of Cardiovascular Research, Istituto Mario Negri, Milano, Italy (M.G.F.).
ORCID
Venue
Circulation
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2008-11-11
Volume
118
Issue
20
Pages
2029-2037
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
DOI
10.1161/circulationaha.107.750000
OpenAlex
W2103053426
Cited by
870
References
22
Citations by year
2026: 5 · 2025: 22 · 2024: 11 · 2023: 20 · 2022: 26 · 2021: 36 · 2020: 33 · 2019: 43 · 2018: 61 · 2017: 62 · 2016: 71 · 2015: 87 · 2014: 78 · 2013: 89 · 2012: 68
FWCI
38.08
Type
journal article
Language
en
Open access
closed
Locations
  • Circulation (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
  • Health Sciences › Medicine › Epidemiology › Acute Ischemic Stroke Management
  • Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
Keywords
oral anticoagulation, atrial fibrillation, time in therapeutic range, antiplatelet therapy, vascular events, treatment benefit, inter-center variability, country-level variation, stroke prevention, quality of care variation, irbesartan, warfarin, aspirin
MeSH terms
Clopidogrel, Administration, Oral, Aged, Aged, 80 and over, Anticoagulants, Aspirin, Atrial Fibrillation, Brazil, Drug Therapy, Combination, Europe, Humans, Middle Aged, North America, Platelet Aggregation Inhibitors, Quality Control, South Africa, Ticlopidine, Time Factors, Treatment Outcome, International Normalized Ratio

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review